

29 April 2021

**Announcements**  
**Australian Securities Exchange**  
**20 Bridge Street**  
**SYDNEY NSW 2000**

**Market announcement – Progress of its clinical programs by subsidiary company, OncoTex Inc.**

iQ3Corp Ltd (ASX:IQ3) is pleased to announce that OncoTEX Inc, a US oncology therapeutic company, in which iQ3Corp Ltd. holds 40.5% equity position, has signed a manufacturing agreement with **Sterling Pharma Solutions** to commence preclinical production of its novel platinum-resistant drug candidate, OxaliTEX, and is in final partnership discussions with a world-class clinical research organization for preclinical and regulatory activities.

The partnership with Sterling Pharma Solutions will facilitate the production of OxaliTEX that meets the FDA regulatory requirements necessary for clinical use. Manufacturing is the first development step in the multistep process that will culminate with an Investigative New Drug (INDA) application that will be submitted to the FDA.

OxaliTEX is being developed in Texas by US oncology therapeutic company, OncoTEX Inc (**OncoTEX**), from their world-first oncology drug platform, TEX Core. OncoTEX is developing the TEX Core platform which is capable of generating innovative small molecule therapies capable of overcoming multiple limitations seen within current cancer therapeutics and are highly targeted to tumour cells by conjugating texaphyrin with FDA approved anti-cancer therapeutics.

OxaliTEX is the first clinical candidate developed from the TEX Core platform, designed to target platinum-resistant ovarian cancer tumour cells by overcoming issues associated with the current platinum-based standard of care (SOC) and is being developed for platinum-resistant ovarian cancer. Unlike current platinum-based SOC oncology therapeutics, OxaliTEX is tumour localising, well-tolerated, overcomes platinum-resistance, and is MRI-detectable, allowing clinicians and patients to easily monitor tumour regression during treatment.

In 2020, OncoTEX initiated the screening of OxaliTEX in patient-derived xenografts of colorectal cancer in partnership with **Champions Oncology**. Other discovery partners include **Charles River Labs** which will partner with OncoTEX to evaluate optimal OxaliTEX regimens. The development and discovery of OxaliTEX has been published in high profile peer-reviewed publications such as **Proceedings of the National Academy of Sciences of the United States of America** (2020) and **Chem** (2020). Most recently, we presented preclinical work at the 2021 **National Conference of the American Association of Cancer Research** (AACR).

OncoTEX will bolster its pipeline with three additional drug candidates.

- GemTEX (exploring the use of DNA replication inhibitors)
- ParpTEX (exploring the use of PARP inhibitors) are part of our Chemotherapy program and
- MangaTEX is part of our Photothermal program.

The early discovery and proof of concept efforts are ongoing through a Sponsored Research Agreement with the Jonathan Sessler lab at the **University of Texas at Austin**.

OncoTEX continues to grow its already strong IP portfolio. Since 2019, the composition of OxaliTEX has been granted patent protection in the USA (2019), Mexico (2020), Australia (2021), Singapore (2021) and has a notice of allowance in Israel. The prosecution of the OxaliTEX patent continues in multiple other jurisdictions. In addition, OncoTEX will continue to file IP on all other discoveries out of the TEX Core platform such as MangaTEX which was filed in 2020.

OncoTEX continues to work with the co-inventors of TEX Core and the OncoTEX Scientific Advisory Board consists of experts from **MD Anderson Cancer Center**, University of Texas at Austin, and **UT Dell Medical School**.

“Ovarian cancer is considered an orphan disease meaning few patients are afflicted with it globally, however, the prognosis of those diagnosed is poor and OncoTEX is committed to changing this. Our partnership with Sterling Pharma Solutions is a significant milestone in our preclinical development of OxaliTEX, and will set the foundations to support our future pipeline of drug candidates from the Tex Core platform,” Dr. George Syrmalis, Chief Executive Officer and Chairman of The iQ Group Global, said.

**About iQ3Corp Ltd (ASX: IQ3)**

iQ3Corp is a specialised life science corporate finance and advisory firm bridging capital with science to create the medicines of the future.

**About OncoTEX Inc.**

OncoTEX Inc is an oncology company and member of the iQ Group Global bioscience investment enterprise The iQ Group Global. OncoTEX Inc owns TEX Core, a novel oncology drug platform that enables the development of well-tolerated, MRI-detectable cancer therapeutics that target drug-sensitive and drug-resistant solid tumours. [Find out more](#)



*Translating science into capital and beyond*

**About The iQ Group Global**

The iQ Group Global is a group of companies that find, fund and develop bioscience discoveries to create life-changing medical innovations. Recognised by The Australian Financial Review for the second consecutive year as one of the country's Most Innovative Companies in 2020, The iQ Group Global's flagship innovations include the Biosensor Platform and TEX Core, a first-in-class oncology drug platform with the ability to develop a pipeline of novel oncology compounds. Visit our website: [theiqgroupglobal.com](http://theiqgroupglobal.com)